Summary
Experimental autoimmunity of the CNS has been well characterized — the antigen has been identified, effector cell specificity has been defined, and the relationship between cellular sensitization and antibody production has been partially clarified. In the guinea pig, experimental allergic encephalomyelitis (EAE) is induced by one injection of myelin basic protein in complete Freun ds adjuvant (BP/CFA). If BP/CFA is preceded by repeated injections of basic protein in incomplete Freun’s adjuvant(BP/IFA), EAE is not induced; the guinea pigs survive and ultimately produce antibody. Induction and prevention of EAE as well as antibody induction by this schedule are dependent on the presence of the intact encephalitogenic (T-cell) site in the polypeptide used for sensitization and preimmunization. In contrast, B-cell sites (those peptide sequences which bind antibody) are independent of the T-cell site. At least 5 specific antigenic regions (B-cell sites) have been demonstrated in the BP molecule. High mycobacteria levels bypass the specificity requirement of helper T-cells but cannot bypass the specificity requirement of effector T-cells. In spite of the sophisticated immunologic techniques available, our knowledge of humoral and cellular sensitivity in multiple sclerosis (MS) patients is very limited. The experimental demonstration of an analogy between EAE and MS is weak: a) Demonstration of BP-sensitized cells or BP-specific antibodies in peripheral blood of MS patients has not been successful. b) Anti-myelin serum factors reported to be associated with both disease states (experimental autoimmunity and MS) are clearly not identical. Nevertheless, successful treatment of EAE in animals by BP/IFA injections has encouraged consideration of clinical trials to test the therapeutic value of BP injections in MS patients. If successful, the question will be answered: if unsuccessful, the dilemma still remains.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alvord, E.C., Jr., Acute disseminated encephalomyelitis and “allergic” neuro-encephalopathies, in Handbook of Clinical Neurology (P.J. Vinken and G.W. Bruyn, eds.) North-Holland Publishing Co.,Amsterdam (1970) pp. 500–571.
Alvord, E.C., Jr., Shaw, C.-M., Hrugy, S. and Kies, M.W., Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy, Ann. N. Y. Acad. Sci. 122 (1965) 333–345.
Bernard, C.C.A., Suppressor T cells prevent experimental autoimmune encephalomyelitis in mice, Clin. Exp. Immunol. 29 (1977) 100–109.
Bernard, C.C.A., MacKay, I.R., Whittingham, S. and Brous, P., Durability of immune protection against experimental autoimmune encephalomyelitis, Cell. Immunol. 22 (1976) 297–310.
Carnegie, P.R., Amino acid sequence of the encephalitogenic basic protein from human myelin, Biochem. J. 123 (1971) 57–67.
Chao, L.-P. and Einstein, E.R., Localization of the active site through chemical modification of the encephalitogenic protein, J. Biol. Chem. 245 (1970) 6397–6403.
Coates, A., MacKay, I.R. and Crawford, M., Immune protection against experimental autoimmune encephalomyelitis: optimal conditions and analysis of mechanism, Cell. Immunol. 12 (1974) 370–381.
Driscoll, B.F., Kies, M.W. and Alvord, E.C., Jr., Successful treatment of experimental allergic encephalomyelitis (EAE) in guinea pigs with homologous myelin basic protein, J. Immunol. 112 (1974) 392–397.
Driscoll, B.F., Kies, M.W. and Alvord, E.C., Jr., Adoptive transfer of experimental allergic encephalomyelitis (EAE): prevention of successful transfer by treatment of donors with myelin basic protein, J. Immunol. 114 (1975) 291–292.
Driscoll, B.F., Kies, M.W. and Alvord, E.C., Jr., Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: presence of intact encephalitogenic site is essential, J. Immunol. 117 (1976) 110–114.
Eylar, E.H., Brostoff, S., Hashim, G., Caccam, J. and Burnett, P., Basic Al protein of the myelin membrane. The complete amino acid sequence, J. Biol. Chem. 246 (1971) 5770–5784.
Eylar, E.H., Jackson, J., Rothenberg, B. and Brostoff, S.W., Suppression of the immune response: reversal of the disease state with antigen in allergic encephalomyelitis, Nature 236 (1972) 74–76.
Falk, G.A., Kies, M.W. and Alvord, E.C., Jr., Delayed hypersensitivity to myelin basic protein in the passive transfer of experimental allergic encephalomyelitis, J. Immunol. 101 (1968) 638–644.
Gonatas, N.K. and Howard, J.C., Inhibition of experimental allergic encephalomyelitis in rats severely depleted of T cells, Science 186 (1974) 839–841.
Kies, M.W., Experimental allergic encephalomyelitis, in Biology of Brain Dysfunction ( G.E. Gaull, ed.) Plenum Press, New York (1973) pp. 185–224.
Kies, M.W. and Alvord, E.C., Jr., Prevention of allergic encephalomyelitis by prior injection of adjuvants, Nature 182 (1958) 1106.
Kies, M.W. and Alvord, E.C., Jr., Encephalitogenic activity in guinea pigs of water-soluble protein fractions of nervous tissue, in“Allergic” Encephalomyelitis (M.W. Kies and E.C. Alvord, Jr., eds.) Charles C. Thomas, Springfield, Ill. (1959) pp. 293–299.
Laatsch, R.H., Kies, M.W., Gordon, S. and Alvord, E.C., Jr., The encephalitogenic activity of myelin isolated by ultracentrifugation, J. Exp. Med. 115 (1962) 777–788.
Levine, S., Sowinski, R. and Kies, M.W., Treatment of experimental allergic encephalomyelitis with encephalitogenic basic proteins, Proc. Soc. Exp. Biol. Med. 139 (1972) 506–510.
Lisak, R.P. and Kies, M.W., Mycobacterial suppression of delayed hypersensitivity in experimental allergic encephalomyelitis, Proc. Soc. Exp. Biol. Med. 128 (1968) 214–218.
MacPherson, C.F.C. and Yo, S.-L., Studies on brain antigens. VI. Prevention of experimental allergic encephalomyelitis by a water-soluble spinal cord protein,B1-SCP, J. Immunol. 110 (1973) 1371–1375.
Ortiz -Ortiz, L. and Weigle, W.O., Cellular events in the induction of experimental allergic encephalomyelitis in rats, J. Exp. Med. 144 (1976) 604–616.
Shaw, C.-M., Alvord, E.C., Jr., Kaku, J. and Kies, M.W., Correlation of experimental allergic encephalomyelitis with delayed-type skin sensitivity to specific homologous encephalitogen, Ann. N.Y. Acad. Sci. 122 (1965) 318–331.
Swanborg, R.H., Antigen-induced inhibition of experimental allergic encephalomyelitis. I. Inhibition in guinea pigs injected with non-encephalitogenic modified myelin basic protein, J. Immunol. 109 (1972) 540–546.
Swanborg, R.H., Antigen-induced inhibition of experimental allergic encephalomyelitis. III. Localization of an inhibitory site distinct from the major encephalitogenic determinant of myelin basic protein, J. Immunol. 114 (1975) 191–194.
Swierkosz, J.E. and Swanborg, R.H., Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis J. Immunol. 115 (1975) 631–633.
Teitelbaum, D., Meshorer, A., Hirshfield, T.,Arnon, R. and Sela, M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur. J. Immunol. 1 (1971) 242–248.
Whipple, H.E., ed., Research in Demyelinating Diseases, Ann. N. Y. Acad. Sci. 122 (1965) 1–570.
Witebsky, E., The status of organ specificity, in “Allergic” Encephalomyelitis ( M.W. Kies and E.C. Alvord, eds.) Charles C. Thomas, Springfield, Ill. (1959) pp. 321–347.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
Kies, M.W. (1978). Autoimmunity in Multiple Sclerosis: Do we have an Experimental Model?. In: Palo, J. (eds) Myelination and Demyelination. Advances in Experimental Medicine and Biology, vol 100. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-2514-7_20
Download citation
DOI: https://doi.org/10.1007/978-1-4684-2514-7_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-2516-1
Online ISBN: 978-1-4684-2514-7
eBook Packages: Springer Book Archive